Literature DB >> 9605423

Different moieties of tautomycin involved in protein phosphatase inhibition and induction of apoptosis.

T Kawamura1, S Matsuzawa, Y Mizuno, K Kikuchi, H Oikawa, M Oikawa, M Ubukata, A Ichihara.   

Abstract

The effects of tautomycin and its derivatives on protein phosphatases PP1 and PP2A and their apoptosis-inducing activity toward human leukemia Jurkat cells were examined, and the relationship between chemical structure and function was discussed. Among the compounds we examined, tautomycin was the most potent inhibitor and the most effective inducer of apoptosis. It inhibited PP1 and PP2A enzymatic activity concentration-dependently with IC50 values of 20 and 75 pM, respectively, in the presence of 0.01% Brij-35, and an LC50 value of 1 microM. Esterification of the anhydride moiety of tautomycin markedly increased the IC50 for the protein phosphatases. The C1'-C7' fragment of tautomycin had no inhibitory effect, but the fragment containing the C22-C26 moiety was inhibitory. These results suggest that the C22-C26 moiety is essential for inhibition of protein phosphatase activity and that the anhydride moiety enhances the inhibition. However, the esterification of the anhydride did not decrease, nor did the inclusion of the C22-C26 moiety increase the apoptosis-inducing activity. On the other hand, the C1-C18 moiety of tautomycin was essential for induction of apoptosis, and the conformation and the arrangement of functionalities of the C18-C26 carbon chain affected the apoptosis activity. However, modification of C1-C18, C1-C21, or C1-C26 compounds had little effect on phosphatase inhibitory activity. Our results strongly suggest that different moieties of tautomycin are involved in protein phosphatase inhibition and induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605423     DOI: 10.1016/s0006-2952(97)00539-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Effects of modification of the hydrophobic C-1-C-16 segment of tautomycin on its affinity to type-1 and type-2A protein phosphatases.

Authors:  A Takai; K Tsuboi; M Koyasu; M Isobe
Journal:  Biochem J       Date:  2000-08-15       Impact factor: 3.857

2.  Crystal structures of protein phosphatase-1 bound to nodularin-R and tautomycin: a novel scaffold for structure-based drug design of serine/threonine phosphatase inhibitors.

Authors:  Matthew S Kelker; Rebecca Page; Wolfgang Peti
Journal:  J Mol Biol       Date:  2008-11-01       Impact factor: 5.469

3.  Functional characterization of ttmM unveils new tautomycin analogs and insight into tautomycin biosynthesis and activity.

Authors:  Jianhua Ju; Wenli Li; Qiuping Yuan; Noel R Peters; F Michael Hoffmann; Scott R Rajski; Hiroyuki Osada; Ben Shen
Journal:  Org Lett       Date:  2009-04-02       Impact factor: 6.005

4.  Immunosuppressive effects of tautomycetin in vivo and in vitro via T cell-specific apoptosis induction.

Authors:  Jae-Hyuck Shim; Heung-Kyu Lee; Eun-Ju Chang; Wook-Jin Chae; Jin-Hwan Han; Duck-Jong Han; Tomohiro Morio; Jung-Jin Yang; Alfred Bothwell; Sang-Kyou Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

5.  Differential effects of tautomycetin and its derivatives on protein phosphatase inhibition, immunosuppressive function and antitumor activity.

Authors:  Mingshan Niu; Yan Sun; Bo Liu; Li Tang; Rongguo Qiu
Journal:  Korean J Physiol Pharmacol       Date:  2012-04-24       Impact factor: 2.016

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.